Phospho-c-Jun (Tyr170) Antibody - #AF3094

(1)   (14)  
Product: Phospho-c-Jun (Tyr170) Antibody
Catalog: AF3094
Description: Rabbit polyclonal antibody to Phospho-c-Jun (Tyr170)
Application: WB IHC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 37~45kDa; 36kD(Calculated).
Uniprot: P05412
RRID: AB_2834531

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:1000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(88%)
Clonality:
Polyclonal
Specificity:
Phospho-c-Jun (Tyr170) Antibody detects endogenous levels of c-Jun only when phosphorylated at Tyrosine 170.
RRID:
AB_2834531
Cite Format: Affinity Biosciences Cat# AF3094, RRID:AB_2834531.
Conjugate:
Unconjugated.
Purification:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Activator protein 1; AP 1; AP1; cJun; Enhancer Binding Protein AP1; Jun Activation Domain Binding Protein; JUN; Jun oncogene; JUN protein; Jun proto oncogene; JUN_HUMAN; JUNC; Oncogene JUN; p39; Proto oncogene c jun; Proto oncogene cJun; Proto-oncogene c-jun; Transcription Factor AP 1; Transcription factor AP-1; Transcription Factor AP1; V jun avian sarcoma virus 17 oncogene homolog; V jun sarcoma virus 17 oncogene homolog (avian); V jun sarcoma virus 17 oncogene homolog; V-jun avian sarcoma virus 17 oncogene homolog; vJun Avian Sarcoma Virus 17 Oncogene Homolog;

Immunogens

Immunogen:
Uniprot:

P05412(JUN_HUMAN) >>Visit HPA database.

Gene(ID):
JUN(3725)
Expression:
P05412 JUN_HUMAN:

Expressed in the developing and adult prostate and prostate cancer cells.

Description:
This gene is the putative transforming gene of avian sarcoma virus 17. It encodes a protein which is highly similar to the viral protein, and which interacts directly with specific target DNA sequences to regulate gene expression.
Sequence:
MTAKMETTFYDDALNASFLPSESGPYGYSNPKILKQSMTLNLADPVGSLKPHLRAKNSDLLTSPDVGLLKLASPELERLIIQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAELHSQNTLPSVTSAAQPVNGAGMVAPAVASVAGGSGSGGFSASLHSEPPVYANLSNFNPGALSSGGGAPSYGAAGLAFPAQPQQQQQPPHHLPQQMPVQHPRLQALKEEPQTVPEMPGETPPLSPIDMESQERIKAERKRMRNRIAASKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMNHVNSGCQLMLTQQLQTF

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Sheep
100
Dog
100
Chicken
100
Rabbit
100
Xenopus
88
Zebrafish
71
Horse
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P05412 As Substrate

Site PTM Type Enzyme
T2 Phosphorylation Q13177 (PAK2)
T8 Phosphorylation Q13177 (PAK2)
Y26 Phosphorylation P41240 (CSK)
S37 Phosphorylation
S48 Phosphorylation
K50 Acetylation
K50 Ubiquitination
K56 Sumoylation
S58 Phosphorylation
T62 Phosphorylation
S63 Phosphorylation P45983 (MAPK8) , P45984 (MAPK9) , P06493 (CDK1) , Q15139 (PRKD1) , Q96KB5 (PBK) , Q8TD08 (MAPK15) , Q9H4B4 (PLK3) , P53779 (MAPK10) , Q00526 (CDK3) , P27361 (MAPK3) , Q99986 (VRK1)
K70 Ubiquitination
S73 Phosphorylation Q8TD08 (MAPK15) , P53779 (MAPK10) , Q99986 (VRK1) , P27361 (MAPK3) , P45983 (MAPK8) , Q96KB5 (PBK) , P06493 (CDK1) , Q9H4B4 (PLK3) , P45984 (MAPK9) , Q00526 (CDK3)
T89 Phosphorylation Q13177 (PAK2)
T91 Phosphorylation P45983 (MAPK8)
T93 Phosphorylation P45983 (MAPK8) , Q13177 (PAK2)
T95 Phosphorylation
T131 Phosphorylation
Y170 Phosphorylation P00519 (ABL1) , P41240 (CSK)
K226 Sumoylation
T231 Phosphorylation P68400 (CSNK2A1)
T239 Phosphorylation P49840 (GSK3A) , P49841 (GSK3B)
S243 Phosphorylation P06493 (CDK1) , P49841 (GSK3B) , P68400 (CSNK2A1) , Q92630 (DYRK2) , P49840 (GSK3A)
S249 Phosphorylation P68400 (CSNK2A1) , P78527 (PRKDC) , P49840 (GSK3A)
K254 Sumoylation
K268 Acetylation
C269 S-Nitrosylation
K271 Acetylation
K273 Acetylation
T286 Phosphorylation Q13177 (PAK2)
K309 Ubiquitination
C320 S-Nitrosylation

Research Backgrounds

Function:

Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation. Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells. Binds to the USP28 promoter in colorectal cancer (CRC) cells.

PTMs:

Ubiquitinated by the SCF(FBXW7), leading to its degradation. Ubiquitination takes place following phosphorylation, that promotes interaction with FBXW7.

Phosphorylated by CaMK4 and PRKDC; phosphorylation enhances the transcriptional activity. Phosphorylated by HIPK3. Phosphorylated by DYRK2 at Ser-243; this primes the protein for subsequent phosphorylation by GSK3B at Thr-239. Phosphorylated at Thr-239, Ser-243 and Ser-249 by GSK3B; phosphorylation reduces its ability to bind DNA. Phosphorylated by PAK2 at Thr-2, Thr-8, Thr-89, Thr-93 and Thr-286 thereby promoting JUN-mediated cell proliferation and transformation. Phosphorylated by PLK3 following hypoxia or UV irradiation, leading to increase DNA-binding activity.

Acetylated at Lys-271 by EP300.

Subcellular Location:

Nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in the developing and adult prostate and prostate cancer cells.

Subunit Structure:

Heterodimer with either FOS or BATF3 or ATF7. The ATF7/JUN heterodimer is essential for ATF7 transactivation activity. Interacts with DSIPI; the interaction inhibits the binding of active AP1 to its target DNA (By similarity). Interacts with HIVEP3 and MYBBP1A (By similarity). Interacts with SP1, SPIB and TCF20. Interacts with COPS5; the interaction leads indirectly to its phosphorylation. Component of the SMAD3/SMAD4/JUN/FOS/complex which forms at the AP1 promoter site. The SMAD3/SMAD4 heterodimer acts synergistically with the JUN/FOS heterodimer to activate transcription in response to TGF-beta. Interacts (via its basic DNA binding and leucine zipper domains) with SMAD3 (via an N-terminal domain); the interaction is required for TGF-beta-mediated transactivation of the SMAD3/SMAD4/JUN/FOS/complex. Interacts with methylated RNF187. Binds to HIPK3. Interacts (when phosphorylated) with FBXW7. Found in a complex with PRR7 and FBXW7. Interacts with PRR7 and FBXW7; the interaction inhibits ubiquitination-mediated JUN degradation promoting its phosphorylation and transcriptional activity. Interacts with RBM39 (By similarity). Interacts with PAGE4.

Family&Domains:

Belongs to the bZIP family. Jun subfamily.

Research Fields

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Tight junction.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Wnt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Substance dependence > Cocaine addiction.

· Human Diseases > Substance dependence > Amphetamine addiction.

· Human Diseases > Infectious diseases: Bacterial > Epithelial cell signaling in Helicobacter pylori infection.

· Human Diseases > Infectious diseases: Bacterial > Salmonella infection.

· Human Diseases > Infectious diseases: Bacterial > Pertussis.

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Choline metabolism in cancer.   (View pathway)

· Human Diseases > Immune diseases > Inflammatory bowel disease (IBD).

· Human Diseases > Immune diseases > Rheumatoid arthritis.

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Th1 and Th2 cell differentiation.   (View pathway)

· Organismal Systems > Immune system > Th17 cell differentiation.   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Estrogen signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Oxytocin signaling pathway.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

References

1). Medium & long-chain acylcarnitine's relation to lipid metabolism as potential predictors for diabetic cardiomyopathy: a metabolomic study. Lipids in Health and Disease, 2021 (PubMed: 34727932) [IF=4.5]

Application: WB    Species: Rat    Sample: H9c2 cells

Fig. 5 C14 can inhibit the AMPK/ACC/CPT1-b signaling pathway and causes lipid accumulation. A The expressions of P-AMPK, AMPK, P-ACC, ACC, and CPT1-b in each group (n = 6), as detected by the western blotting. B-D Quantification of p-AMPK, AMPK, p-ACC, ACC, and CPT1-b. E The levels of CPT1-b in H9c2, as analyzed by Immunofluorescence staining (n = 6, Scale bar = 100 μm). G The statistical analysis shows the positive expression of CPT1-b in H9c2. F, H TUNEL staining and positive cell Quantitative analysis (n = 6, Scale bar = 100 μm). I-J The expressions of Bcl-2, Bax, and Cleaved-caspase 3 were analyzed by immunoblotting in H9c2 in each group (n = 6). Data are represented as means ± SD, two-way ANOVA followed by Tukey’s post hoc test was used. *P < 0.05, **P < 0.01, and ***P < 0.001

Application: IF/ICC    Species: Rat    Sample: H9c2 cells

Fig. 5 C14 can inhibit the AMPK/ACC/CPT1-b signaling pathway and causes lipid accumulation. A The expressions of P-AMPK, AMPK, P-ACC, ACC, and CPT1-b in each group (n = 6), as detected by the western blotting. B-D Quantification of p-AMPK, AMPK, p-ACC, ACC, and CPT1-b. E The levels of CPT1-b in H9c2, as analyzed by Immunofluorescence staining (n = 6, Scale bar = 100 μm). G The statistical analysis shows the positive expression of CPT1-b in H9c2. F, H TUNEL staining and positive cell Quantitative analysis (n = 6, Scale bar = 100 μm). I-J The expressions of Bcl-2, Bax, and Cleaved-caspase 3 were analyzed by immunoblotting in H9c2 in each group (n = 6). Data are represented as means ± SD, two-way ANOVA followed by Tukey’s post hoc test was used. *P < 0.05, **P < 0.01, and ***P < 0.001

Application: WB    Species: Rat    Sample: H9c2 cells

Fig. 5 C14 can inhibit the AMPK/ACC/CPT1-b signaling pathway and causes lipid accumulation. A The expressions of P-AMPK, AMPK, P-ACC, ACC, and CPT1-b in each group (n = 6), as detected by the western blotting. B-D Quantification of p-AMPK, AMPK, p-ACC, ACC, and CPT1-b. E The levels of CPT1-b in H9c2, as analyzed by Immunofluorescence staining (n = 6, Scale bar = 100 μm). G The statistical analysis shows the positive expression of CPT1-b in H9c2. F, H TUNEL staining and positive cell Quantitative analysis (n = 6, Scale bar = 100 μm). I-J The expressions of Bcl-2, Bax, and Cleaved-caspase 3 were analyzed by immunoblotting in H9c2 in each group (n = 6). Data are represented as means ± SD, two-way ANOVA followed by Tukey’s post hoc test was used. *P < 0.05, **P < 0.01, and ***P < 0.001

Application: IF/ICC    Species: Rat    Sample: H9c2 cells

Fig. 7 AICAR reduces lipid accumulation by alleviates the C14 mediated inhibition of the AMPK/ACC/CPT1 signaling pathway. A Western blotting was used to detect the expressions of P-AMPK, AMPK, P-ACC, ACC, and CPT1-b in each group (n = 6). B-D Quantification of p-AMPK, AMPK, p-ACC, ACC, and CPT1-b expressions. E The levels of CPT1-b in H9c2 were explored by immunofluorescence staining (n = 6, Scale bar = 100 μm). F The statistical analysis represents the positive expression of CPT1-b in H9c2. Data are represented as means ± SD, where two-way ANOVA followed by Tukey’s post hoc test was used. *P < 0.05, **P < 0.01, and ***P < 0.001

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.